Emergent BioSolutions Inc.
EBS
$9.13
-$0.105-1.14%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.00M | 68.00M | -31.30M | 114.80M | -283.10M |
| Total Depreciation and Amortization | 23.50M | 25.40M | 26.00M | 26.40M | 28.50M |
| Total Amortization of Deferred Charges | 2.40M | 2.30M | 2.20M | -6.70M | 5.00M |
| Total Other Non-Cash Items | -3.20M | 11.80M | 8.50M | -46.40M | 91.20M |
| Change in Net Operating Assets | 95.70M | -118.70M | -85.30M | 65.60M | 205.90M |
| Cash from Operations | 106.40M | -11.20M | -79.90M | 153.70M | 47.50M |
| Capital Expenditure | -2.90M | -3.60M | -1.70M | -5.80M | -4.60M |
| Sale of Property, Plant, and Equipment | 20.10M | 68.10M | 300.00K | 7.60M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 0.00 | 110.20M | -- |
| Other Investing Activities | 0.00 | -5.00M | 30.00M | -- | -- |
| Cash from Investing | 17.20M | 59.50M | 28.60M | 112.00M | -4.60M |
| Total Debt Issued | -- | -- | 0.00 | 219.00M | 15.00M |
| Total Debt Repaid | -- | -- | 0.00 | -413.00M | -60.50M |
| Issuance of Common Stock | 700.00K | 100.00K | 800.00K | 9.30M | 700.00K |
| Repurchase of Common Stock | -7.10M | -500.00K | -300.00K | -300.00K | -200.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 4.70M | -5.90M |
| Cash from Financing | -6.40M | -400.00K | 500.00K | -180.30M | -50.90M |
| Foreign Exchange rate Adjustments | 1.00M | -700.00K | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.20M | 47.20M | -50.80M | 85.40M | -8.00M |